Quick Answer
Lineage Cell Therapeutics, Inc. reported R&D Expense of $17.73 million for fiscal year 2025.
Lineage Cell Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $17.73M | +42.2% |
| 2024 | $12.47M | -20.6% |
| 2023 | $15.71M | +12.3% |
| 2022 | $13.99M | -58.8% |
| 2021 | $33.91M | +175.3% |
| 2020 | $12.32M | -31.4% |
| 2019 | $17.95M | -14.3% |
| 2018 | $20.95M | -12.8% |
| 2017 | $24.02M | -33.5% |
| 2016 | $36.11M | -15.3% |
| 2015 | $42.60M | +13.5% |
| 2014 | $37.53M | +41.1% |
| 2013 | $26.61M | +46.9% |
| 2012 | $18.12M | +32.2% |
| 2011 | $13.70M | +67.2% |
| 2010 | $8.19M | +357.4% |
| 2009 | -$3.18M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.27M | +3.2% | +5.3% |
| June 30, 2025 | $3.11M | +8.3% | -0.3% |
| March 31, 2025 | $3.11M | +3.5% | -1.8% |
| September 30, 2024 | $3.17M | -15.2% | +10.6% |
| June 30, 2024 | $2.87M | -25.9% | -4.7% |
| March 31, 2024 | $3.01M | -28.1% | -19.5% |
| September 30, 2023 | $3.74M | +4.1% | -3.4% |
| June 30, 2023 | $3.87M | +17.3% | -7.5% |
- Lineage Cell Therapeutics, Inc. showed an increase of +42.2% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, Lineage Cell Therapeutics, Inc.’s r&d expense has grown by 657.2% (from -$3.18 million to $17.73 million).
- The most recent figure is from Lineage Cell Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: